Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial

BACKGROUND: Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer associated with poor survival outcomes in patients with distant metastatic disease (mMCC). In an initial analysis from JAVELIN Merkel 200, a phase 2, prospective, open-label, single-arm trial in mMCC, avelumab—a human anti–pro...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Immunother Cancer
Main Authors: Kaufman, Howard L., Russell, Jeffery S., Hamid, Omid, Bhatia, Shailender, Terheyden, Patrick, D’Angelo, Sandra P., Shih, Kent C., Lebbé, Céleste, Milella, Michele, Brownell, Isaac, Lewis, Karl D., Lorch, Jochen H., von Heydebreck, Anja, Hennessy, Meliessa, Nghiem, Paul
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2018
Assuntos:
Short Report
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5774167/
https://ncbi.nlm.nih.gov/pubmed/29347993
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-017-0310-x
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares